Chlamydia pneumoniae seropositivity and cardiovascular risk factors: The InCHIANTI study

Journal of the American Geriatrics Society

Volumn 52, Issue 10, 2004, Pages 1626-1631

  Blanc, Pierluigi ^a   Corsi, Anna Maria ^b   Gabbuti, Andrea ^a   Peduzzi, Cecilia ^a   Meacci, Francesca ^a   Olivieri, Fabiola ^b   Lauretani, Fulvio ^b   Francesco, Mazzotta ^a   Ferrucci, Luigi ^b,c,d  

^a Istituto Statale SS Annunziata   (Italy)

^b INRCA   (Italy)

^c NATIONAL INSTITUTE ON AGING   (United States)

^d HARBOR HOSPITAL   (United States)

Author keywords

Chlamydia pneumoniae; Cytokines; Elderly; Inflammation

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; FERRITIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; IRON; TUMOR NECROSIS FACTOR ALPHA; CYTOKINE;

ADULT; AGED; BODY MASS; CARDIOVASCULAR RISK; CHLAMYDOPHILA PNEUMONIAE; CONTROLLED STUDY; GEOGRAPHY; HUMAN; HYPERTENSION; IMMUNOFLUORESCENCE; NONHUMAN; PREVALENCE; REVIEW; SEROLOGY; SMOKING; AGE DISTRIBUTION; ARTICLE; BLOOD; CARDIOVASCULAR DISEASE; CHLAMYDIASIS; CROSS-SECTIONAL STUDY; EPIDEMIOLOGY; FEMALE; IMMUNOLOGY; ITALY; MALE; MIDDLE AGED; RISK FACTOR; SEX RATIO;

ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CHLAMYDIA INFECTIONS; CHLAMYDOPHILA PNEUMONIAE; CROSS-SECTIONAL STUDIES; CYTOKINES; FEMALE; HUMANS; HYPERTENSION; ITALY; MALE; MIDDLE AGED; RISK FACTORS; SEROEPIDEMIOLOGIC STUDIES; SEX DISTRIBUTION;

EID: 6944247812     PISSN: 00028614     EISSN: 15325415     Source Type: Journal    
DOI: 10.1111/j.1532-5415.2004.52453.x     Document Type: Review

References (50)

1. Kuo CC, Jackson LA, Campbell LE et al. Chlamydia pneumonias (TWAR). Clin Microbiol Rev 1995;8:451-461.
2. Choi TY, Kim DA, Kim SK et al. Prevalence of specific antibodies to Chlamydia pneumonias in Korea. J Clin Microbiol 1998;36:3426-3428.
3. Grayston JT. Background and current knowledge of Chlamydia pneumonias and atherosclerosis. J Infect Dis 2000;181:S402-S410.
4. Koh WP, Taylor MB, Hughes K et al. Seroprevalence of IgG against Chlamydia pneumonias in Chinese Malays and Asian Indians in Singapore. Int J Epidemiol 2002;31:1001-1007.
5. Leinonen M, Saikku P. Interaction of Chlamydia pneumonias infection with other risk factors of atherosclerosis. Am Heart J 1999;138:S504-S506.
6. Einarsson S, Sigurdsson HK, Magnusdottir SD et al. Age specific prevalence of antibodies against Chlamydia pneumonias in Iceland. Scand J Infect Dis 1994;26:393-397.
7. Wang JH, Liu YC, Cheng DL et al. Seroprevalence of Chlamydia pneumonias in Taiwan. Scand J Infect Dis 1993;25:565-568.
8. Laurila A, Bloigu A, Näyhä S et al. Chlamydia pneumonias antibodies and serum lipids in Finnish men: Cross sectional study. BMJ 1997;314:1456-1457.
9. Murray LJ, O'Reilly DPJ, Ong GML et al. Chlamydia pneumonias antibodies are associated with an atherogenic lipid profile. Heart 1999;81:239-244.
10. Cook PJ, Lip GYH, Davies P et al. Chlamydia pneumoniae antibodies in severe essential hypertension. Hypertension 1998;31:589-594.
11. Dart AM, Martin JL, Kay S. Association between past infection with Chlamydia pneumonias and body mass index, low-density lipoprotein particle size and fasting insulin. Int J Obes 2002;26:464-468.
12. Ngeh J, Anand V, Gupta S. Chlamydia pneumonias and atherosclerosis-what we know and what we don't. Clin Microbiol Infect 2002;8:2-13.
13. Boman J, Hammerschlag MR. Chlamydia pneumoniae and atherosclerosis: Critical assessment of diagnostic methods and relevance to treatment studies. Clin Microbiol Rev 2002;15:1-20.
14. Heinemann M, Susa M, Simnacher U et al. Growth of Chlamydia pneumoniae induces cytokine production and expression of CD 14 in a human monocytic cell line. Infect Immun 1996;64:4872-4875.
15. Kaukoranta-Tolvanen SS, Teppo AM, Laitinen K et al. Growth of Chlamydia pneumoniae in cultured human peripheral blood mononuclear cell and induction of a cytokines response. Microb Pathog 1996;21:215-221.
16. Ferrucci L, Bandinelli S, Benvenuti E et al. Subsystems contributing to the decline in ability to walk: Bridging the gap between epidemiology and geriatric practice in the InCHIANTI study. J Am Geriatr Soc 2000;48:1618-1625.
17. Ridker PM, Cushman M, Stampfer MJ et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997;336:973-979.
18. Salonen JT, Nyyssonen K, Korpela H et al. High stored iron levels are associated with excess risk of myocardial infarction in eastern Finnish men. Circulation 1992;86:803-811.
19. Corti MC, Guralnik JM, Salive ME et al. Serum iron level, coronary artery disease, and all-cause mortality in older men and women. Am J Cardiol 1997;79:120-127.
20. Sullivan JP, Weinberg ED. Iron and role of Chlamydia pneumoniae in heart disease. Emerg Infect Dis 1999;5:724-726.
21. Weinberg ED. Iron loading and disease surveillance. Emerg Infect Dis 1999;46:231-238.
22. Lohman TG, Roche AF, Martorell R, eds. Anthropometric Standardization Reference Manual. Champaign, IL: Human Kinetics Books, 1988.
23. Chumlea WC, Steinbaugh ML, Roche AF et al. Nutritional Assessment of the Elderly Through Anthropometry, 2nd Ed. Columbus, OH: Ross Laboratories, 1984.
24. Kanamoto Y, Ouchi K, Mizui M et al. Prevalence of antibody to Chlamydia pneumoniae TWAR in Japan. J Clin Microbiol 1991;29:816-818.
25. Paltiel O, Kark JD, Leinonen M et al. High prevalence of antibodies to Chlamydia pneumoniae: Determinants of IgG and IgA seropositivity among Jerusalem residents. Epidemiol Infect 1995;114:465-473.
26. Ferrari M, Poli A, Olivieri M et al. Seroprevalence of Chlamydia pneumoniae antibodies in a young adult population sample living in Verona. European Community Respiratory Health Survey (ECRHS) Verona. Infection 2000;28:38-41.
27. Patel P, Mendall MA, Carrington D et al. Association of Helicobacter pylori and Chlamydia pneumoniae infections with coronary heart disease and cardiovascular risk factors. BMJ 1995;311:711-714.
28. Nishimura M, Ushiyama M, Nanbu A et al. Inverse association of Chlamydia pneumoniae infection with high blood pressure in Japanese adults. Am J Hypertens 2001;14:20-26.
29. Pitiriga VC, Kotsis VT, Alexandrou ME et al. Increased prevalence of Chlamydia pneumoniae but not Epstein-Barr antibodies in essential hypertensives. J Hum Hypertens 2003;17:21-27.
30. Pitiriga VC, Kotsis VT, Papamichail CM et al. High prevalence of Chlamydia pneumoniae antibodies in white-coat hypertensives. Atherosclerosis 2003;167:231-235.
31. Saikku P, Leinonenm M, Mattila K et al. Serological evidence of an association of a novel chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction. Lancet 1988;2:983-986.
32. Saikku P, Leinonen M, Tenkanen L et al. Chronic Chlamydia pneumoniae infection as a risk factor for coronary heart disease in the Helsinki Heart Study. Ann Intern Med 1992;116:273-278.
33. Mendall MA, Carrington D, Strachan D et al. Chlamydia pneumoniae: Risk factors for seropositivity and association with coronary heart disease. J Infect 1995;30:121-128.
34. Danesh J, Collins R, Peto R. Chronic infections and coronary heart disease: Is there a link? Lancet 1997;350:430-436.
35. Miyashita N, Toyota E, Sawayama T et al. Association of chronic infection of Chlamydia pneumoniae and coronary heart disease in the Japanese. Intern Med 1998;37:913-916.
36. Cook PJ, Honeybourne D, Lip GY et al. Chlamydia pneumoniae antibody liters are significantly associated with acute stroke and transient cerebral ischemia. The West Birmingham Stroke Project. Stroke 1998;29:404-410.
37. Saikku P. Epidemiologic association of Chlamydia pneumoniae and atherosclerosis: The initial serologic observation and more. J Infect Dis 2000;181:S411-S413.
38. Sessa R, Di Pietro M, Schiavoni G et al. Prevalence of Chlamydia pneumoniae in peripheral blood mononuclear cells in Italian patients with acute ischaemic heart disease. Atherosclerosis 2001;159:521-525.
39. Kalayoglu MV, Libby P, Byrne GI. Chlamydia pneumoniae as an emerging risk factor in cardiovascular disease. JAMA 2002;288:2724-2731.
40. Badiaga S, Paganelli F, Parola Pey al. Chlamydia pneumoniae, but not Bartonella quintana, is associated with coronary heart disease: Results of a French case-control study. Clin Microbiol Infect 2003;9:315-318.
41. Young JL, Libby P, Schonbeck U. Cytokines in the pathogenesis of atherosclerosis. Thromb Haemost 2002;88:554-567.
42. Schumacher A, Seljeflot I, Lerkerod AB et al. Positive Chlamydia pneumoniae serology is associated with elevated levels of tumor necrosis factor alpha in patients with coronary heart disease. Atherosclerosis 2002;164:153-160.
43. Dixit VM, Green S, Sarma V et al. Tumor necrosis factor-alpha induction of novel gene products in human endothelial cells including a macrophage-specific chemotaxin. J Biol Chem 1990;265:2973-2978.
44. Jones SA, Rose-John S. The role of soluble receptors in cytokine biology: The agonistic properties of the sIL-6r complex. Biochim Biophys Acta 2002;1592:251-263.
45. Jones SA, Horiuchi S, Toplay N et al. The soluble interleukin 6 receptor: Mechanism of production and implications in disease. FASEB J 2001;15:43-58.
46. Walev I, Vollmer P, Palmer M et al. Pore-forming toxins trigger shedding of receptors for interleukin 6 and lipopolysaccaride. Proc Natl Acad Sci U S A 1996;93:7882-7887.
47. Modur V, Li Y, Zimmerman GA et al. Retrograde inflammatory signaling from neutrophils to endothelial cells by soluble interleukin-6 receptor alpha. J Clin Invest 1997;100:2752-2756.
48. Mullberg J, Durie FH, Otten-Evans C. A metalloprotease inhibitor blocks shedding of the IL-6 receptor and the p60 TNF receptor. J Immunol 1995;155:5198-5205.
49. Klouche M, Bhakdi S, Hemmes M et al. Novel path to activation of vascular smooth muscle cells: Up-regulation of gp130 creates an autocrine activation loop by IL-6 and its soluble receptor. J Immunol 1999;163:4583-4589.
50. Romano M, Sironi M, Toniatti C et al. Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment. Immunity 1997;6:315-325.